Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 100 shares, a drop of 80.0% from the February 13th total of 500 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily volume of 1,000 shares, the short-interest ratio is currently 0.1 days.
Ipsen Stock Up 0.9 %
Shares of OTCMKTS:IPSEY traded up $0.26 during midday trading on Friday, hitting $29.79. The company had a trading volume of 452 shares, compared to its average volume of 733. Ipsen has a 12 month low of $27.11 and a 12 month high of $34.06. The firm has a fifty day simple moving average of $30.27 and a 200 day simple moving average of $29.95.
About Ipsen
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Further Reading
Before you consider Ipsen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ipsen wasn't on the list.
While Ipsen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
